

1 May 2015

Appendix 3B

Atlas Pearls and Perfumes Ltd (ASX: ATP) ("Atlas" or the "Company") wishes to advise the issue of a total of 69,123,612 new fully paid ordinary shares ("Shares") at \$0.045 each has occurred today raising approximately \$3.1 million (before costs).

16,074,730 Shares have been issued for which valid applications were received from Atlas eligible Shareholders under the fully underwritten 1 for 5 non-renounceable pro rata entitlement offer of fully paid ordinary shares in the Company at an offer price of \$0.045 per Share which opened on 25 March 2015 and closed on 24 April 2015 ("Entitlement Offer"). A further 53,048,882 Shares were issued to the underwriter of the Entitlement Offer. The terms of this underwriting and its impact on the Company were set out in detail in the Entitlement Offer Prospectus, a copy of which was released to ASX on 16 March 2015.

The Board wishes to thank all Shareholders that participated in the Entitlement Offer.

An Appendix 3B is attached to this ASX announcement.

- END -

ABOUT ATLAS PEARLS AND PERFUMES LTD

Atlas Pearls and Perfumes ("Atlas") is an Australian based pearling and perfume business established in 1992. Atlas has earned an enviable reputation as a world leading pearl producer of "nature's most precious gift", the South Sea pearl, specialising in highly sought after white and silver pearls. Atlas operates pearl farms spread across the Indonesian archipelago, including Bali, Flores, and West Papua. Atlas is a fully integrated pearling business. The Company has its own high quality grading and loose pearl distribution business, a jewellery manufacturing capability and sells direct to customers through wholesale partners and via its retail outlets. In 2012, the Company expanded its operations into perfumes and is currently developing a range of propriety products which include pearl powder (cosmetics and nutraceuticals), pearl proteins (cosmetics), pearl volatiles and boronia (perfumes) for supply into the global luxury supply chain.

For more information please visit: www.atlaspearlsandperfumes.com.au

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12$

Name	of entity	
Atlas Pearls and Perfumes Ltd		
ABN		
32 00	9 220 053	
We (t	the entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares.
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	69,123,612 Fully paid ordinary shares.
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares.

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes - Fully paid ordinary shares.
5	Issue price or consideration	\$0.045 per share.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of 16,074,730 fully paid ordinary shares to shareholders under the fully underwritten 1 for 5 non-renounceable pro rata entitlement offer (Entitlement Offer) which opened on 25 March 2015 and closed on 24 April 2015 and 53,048,882 fully paid ordinary shares issued to the underwriter as announced to ASX on 29 April 2015. The terms of this underwriting and its impact on the Company were set out in detail in the Entitlement Offer Prospectus, a copy of which was released to ASX on 16 March 2015.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	1 May 2015	
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	Number 414,740,064	⁺ Class Fully paid ordinary shares (ASX code: ATP)

⁺ See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (*including* the securities in section 2 if applicable)

Number	+Class
150,000	Convertible notes.
20,000,000	Unlisted options exercisable at \$0.0858 each on or before 31 December 2016.
8,500,000	Unlisted options exercisable at \$0.095 each on or before 31 December 2016.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Dividends are paid as authorised by Directors.

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
	<u> </u>	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
	_	
15	⁺ Record date to determine entitlements	
	<u></u>	
16	Will holdings on different registers (or subregisters) be aggregated for calculating	
	entitlements?	
17	Policy for deciding entitlements in relation to fractions	
	<u> </u>	

18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	

⁺ See chapter 19 for defined terms.

30	How do *security holders sell their entitlements in full through a broker?
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?
32	How do ⁺ security holders dispose of their entitlements (except by sale through a broker)?
33	[†] Despatch date
	Type of securities (tick one)
(a)	Securities described in Part 1
(b)	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully pa employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertil securities
Entit	ies that have ticked box 34(a)
Addi	tional securities forming a new class of securities
Tick to	o indicate you are providing the information or nents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the addition *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000
	10,001 - 100,000 100,001 and over

37	A copy of any trust deed for the additional *securities			
Entiti	Entities that have ticked box 34(b)			
38	Number of securities for which †quotation is sought	N/A		
39	Class of *securities for which quotation is sought			
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?			
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment			
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period			
	(if issued upon conversion of another security, clearly identify that other security)			
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	+Class	

Quotation agreement

⁺ See chapter 19 for defined terms.

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

== == == ==

Sign here:		2015
Print name:	SUSAN HUNTER	

NO11 1

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	Not applicable.	
 Add the following: Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	Not applicable.	
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Not applicable.	
"A"	Not applicable.	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	Not applicable.	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Not applicable.	
• Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	Not applicable.	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	Not applicable.	
Note: number must be same as shown in Step 2		
Subtract "C"	Not applicable.	
Note: number must be same as shown in Step 3		
Total ["A" x 0.15] – "C"	Not applicable. [Note: this is the remaining placement capacity under rule 7.1]	

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	Not applicable.	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	Not applicable.	
	Note: this value cannot be changed	
Multiply "A" by 0.10	Not applicable.	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Not applicable.	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	Not applicable	
"E"	Not applicable.	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	Not applicable.
Note: number must be same as shown in Step 2	
Subtract "E"	Not applicable.
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	Not applicable.
	Note: this is the remaining placement capacity under rule 7.1A